Around 15% of pregnant women in the USA (8%-13% in the UK) may have taken antidepressants at some point during their pregnancy. However, the use of these medications remains a controversial topic, with conflicting research highlighting both their potential benefits and risks. In this talk, Prof. David Healy will examine the possible risks antidepressants—particularly SSRIs—pose to fetal development and explore alternative approaches to supporting women struggling with depression or at risk for postnatal depression.
Additionally, Professor Healy will address the often-overlooked dangers associated with acetaminophen (paracetamol) use during pregnancy and its potential impact on infants. Given the widespread use of acetaminophen-based medications like Tylenol and Calpol, particularly in babies, understanding the potential consequences of prenatal exposure is crucial for clinicians providing guidance to expectant mothers. This session will shed light on critical issues that can influence both maternal and infant health outcomes and look at how this might show up in infant behaviour and development.
